SUPPLEMENTARY MATERIAL

Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post-Hoc Analysis from a Large Randomized Clinical Trial

Kurt de Vlam[1], Walter P. Maksymowych[2], Gaia Gallo[3], Proton Rahman[4], Philip Mease[5], Venkatesh Krishnan[3], Conor J. McVeigh[3], Jeffrey Lisse[3], Danting Zhu[3], Rebecca J. Bolce[3], Philip G. Conaghan[6]

Affiliations:

[1]University Hospital Leuven, Leuven, Belgium

[2]Department of Medicine, Division of Rheumatology at the University of Alberta, Alberta, Canada

[3]Eli Lilly and Company, Indianapolis, United States of America

[4]Department of Medicine, Memorial University, St. John's, Newfoundland A1C 5B8, Canada

[5]Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, United States of America

[6]Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, United Kingdom

Corresponding Author: Kurt de Vam

Email Address: kurt.devlam@uzleuven.be

Keywords: IL-17; Pain; Inflammation; Rheumatic Disease; Spondylitis, Ankylosing

Trial Protocol: Prot_000.pdf (clinicaltrials.gov)

Statistical Analysis Plan: SAP_001.pdf (clinicaltrials.gov)

Table S1. Baseline demographics and disease characteristics of participants in COAST-V

	Placebo N=87[a]	Adalimumab Q2W N=90	Ixekizumab Q2W N=83	Ixekizumab Q4W N=81
Age (years)	42·7 (12·0)	41·8 (11·4)	41·3 (11·2)	41·0 (12·1)
Sex, n (%)				
Male	71 (82·6%)	73 (81·1%)	64 (77·1%)	68 (84·0%)
Female	15 (17·4%)	17 (18·9%)	19 (22·9%)	13 (16·0%)
Race, n (%)				
White	52 (60·5%)	57 (63·3%)	52 (62·7%)	52 (64·2%)
Asian	28 (32·6%)	29 (32·2%)	25 (30·1%)	25 (30·9%)
Other	6 (7·0%)	4 (4·4%)	6 (7·2%)	4 (4·9%)
Weight (kg)	79·9 (17·1)	78·2 (17·2)	76·6 (13·8)	77·6 (14·7)
<70 kg, n (%)	25 (29·1)	29 (32·2)	29 (34·9)	24 (29·6)
≥70 kg, n (%)	61 (70·9)	61 (67·8)	54 (65·1)	57 (70·4)
Age of onset of AxSpA (years)	26·4 (8·4)	26·5 (8·6)	25·8 (8·2)	25·4 (7·7)
Duration of symptoms since AxSpA onset (years)	16·6 (10·1)	15·6 (9·3)	15·8 (10·6)	15·8 (11·2)
Duration of disease since AxSpA diagnosis (years)	6·8 (7·6)	7·5 (7·5)	8·2 (9·0)	8·3 (9·6)
Positive for HLA-B27	76 (89·4%)	82 (91·1%)	75 (90·4%)	75 (92·6%)
NSAID use at baseline, n (%)	78 (90·7%)	83 (92·2%)	79 (95·2%)	72 (88·9%)
csDMARDs use at baseline, n (%)	31 (36·0%)	32 (35·6%)	29 (34·9%)	33 (40·7%)
Sulfasalazine, n (%)	23 (26·7%)	25 (27·8%)	25 (30·1%)	24 (29·6%)
Methotrexate, n (%)	8 (9·3%)	8 (8·9%)	4 (4·8%)	9 (11·1%)
Patient global assessment of disease activity NRS	7·1 (1·7)	7·1 (1·7)	7·1 (1·6)	6·9 (1·5)
CRP (mg/L)	16·0 (21·0)	12·5 (17·6)	13·4 (15·3)	12·2 (13·3)
CRP >5 mg/L, n (%)	60 (69·8)	52 (57·8)	55 (66·3)	52 (64·2)
ASDAS	3·9 (0·7)	3·7 (0·8)	3·8 (0·8)	3·7 (0·7)
BASDAI	6·8 (1·2)	6·7 (1·5)	6·7 (1·6)	6·8 (1·3)
BASFI	6·4 (1·9)	6·1 (2·1)	6·3 (2·1)	6·1 (1·8)
ASAS Health Index	8·1 (3·5)	8·2 (3·7)	8·4 (3·6)	7·5 (3·3)
SF-36 PCS	32·0 (8·3)	33·5 (8·3)	34·1 (7·6)	34·0 (7·5)
MRI SPARCC Spine	15·8 (21·2)	20·0 (28·4)	16·6 (23·8)	14·5 (20·6)
MRI SPARCC SIJ	5·0 (9·6)	4·7 (11·2)	6·4 (10·9)	4·5 (9·1)
Spinal pain	7.4 (1.4)	7.0 (1.6)	7.1 (1.5)	7.2 (1.3)
Spinal pain at night	7.1 (1.7)	6.9 (1.8)	7.1 (1.7)	7.0 (1.4)
Bodily pain[b]	35.4 (17.7)	37.6 (15.7)	38.0 (16.9)	38.8 (16.3)

Unless otherwise indicated, values are presented as mean (SD). Data are presented for patients with non-missing values.

[a]The placebo population excludes one patient who was a screen failure and was accidentally randomised to placebo. This patient discontinued prior to receiving study drug.

[b]Measured using the SF-36 PCS associated domains.

Abbreviations: ASAS, Assessment of SpondyloArthritis International Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; AxSpA, Axial Spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C-

reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; HLA, human leukocyte antigen; MRI, magnetic resonance imaging; NRS, numeric rating scale; NSAID, nonsteroidal anti-inflammatory drug; Q2W, every two weeks; Q4W, every four weeks; SD, Standard deviation; SF-36 PCS, Medical Outcomes Study 36-item Short-Form Health Survey Physical Component Summary; SIJ, Sacroiliac joint; SPARCC, Spondyloarthritis Research Consortium of Canada.

Figure S1. Trial Profile for COAST-V